Bluebird bio, Inc. (BLUE) Higher stock upon receipt of European Commission marketing authorization for SKYSONA
What is going on with bluebird bio, Inc.?
The European Commission has granted marketing authorization to bluebird bio, Inc. (BLUE) for SKYSONA for the treatment of early cerebral adrenoleukodystrophy (CALD). Adrenoleukodystrophy (ALD), which affects males, mutates genes and then subsequently affects adrenoleukodystrophy protein production, resulting in toxic build-up of very long-chain fatty acids in the adrenal gland, as well as in the adrenal gland. spinal cord and in the white matter of the brain. Before the market this morning, BLUE stock was trading at $ 28.07, up 2.71% from the previous day.
What does this mean for BLUE?
“SKYSONA is the first and only unique gene therapy approved in the EU for patients with CALD, a devastating neurodegenerative disease, and we are extremely grateful to everyone who brought us to this milestone, patients and their families. relatives to all study researchers, regulators, the ALD community and of course the extended bluebird family, ”said Andrew Obenshain, President, Serious Genetic Diseases, Bluebird Bio.
The marketing authorization for SKYSONA is focused on the single gene treatment of the therapy for “patients under 18 years of age with an ABCD1 genetic mutation and for whom a fraternal hematopoietic (blood) stem cell (HLA) compatible with donor human leukocyte antigen (HSC) is not available.
BLUE has an overall score of 41. Find out what that means to you and get the rest of the leaderboard on BLUE!
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for serious and rare genetic diseases. The company’s gene therapy procedures aim to genetically modify a patient’s cells to fundamentally correct or treat the underlying genetic basis of a disease. Bluebird’s revenues are derived from collaboration agreements, research fees, license fees, and grant revenues. The company works with industry peers, strategic partners and not-for-profit organizations in the development and commercialization of its product candidates.
